Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers
- PMID: 9750972
Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers
Abstract
Healthy subjects who panic following systemic cholecystokinin-tetrapeptide (CCK-4) challenge typically exhibit a symptom profile reminiscent of that evident among panic patients. However, the biological concomitants of CCK-4-induced panic in healthy subjects remain obscure. Accordingly, we evaluated the behavioral, cardiovascular, and neuroendocrine effects of CCK-4 in panickers and nonpanickers. Predictably, subjects who panicked with CCK-4 experienced more intense symptoms of panic and greater increases in ratings of fearful and anxious mood than did subjects who did not panic. CCK-4-induced increases in diastolic blood pressure, adrenocorticotropic hormone, prolactin, and growth hormone secretion were also significantly enhanced in subjects who panicked. The results of this study demonstrate that the behavioral experience of CCK-4-induced panic in healthy individuals is accompanied by marked biological changes and provide confirmation that CCK-4 is a useful model of panic for research among nonclinical subjects.
Similar articles
-
Impact of loudness dependency of auditory evoked potentials on the panic response to CCK-4.J Psychiatr Res. 2009 Jan;43(4):393-400. doi: 10.1016/j.jpsychires.2008.04.010. Epub 2008 Jun 4. J Psychiatr Res. 2009. PMID: 18534623 Clinical Trial.
-
Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder.Depress Anxiety. 2004;20(2):51-8. doi: 10.1002/da.20012. Depress Anxiety. 2004. PMID: 15390214 Clinical Trial.
-
Neurohormonal responses to cholecystokinin tetrapeptide: a comparison of younger and older healthy subjects.Psychoneuroendocrinology. 2000 Aug;25(6):633-47. doi: 10.1016/s0306-4530(00)00015-9. Psychoneuroendocrinology. 2000. PMID: 10840174 Clinical Trial.
-
Cholecystokinin and panic disorder: past and future clinical research strategies.Scand J Clin Lab Invest Suppl. 2001;234:19-27. Scand J Clin Lab Invest Suppl. 2001. PMID: 11713976 Review.
-
HPA axis activity in patients with panic disorder: review and synthesis of four studies.Depress Anxiety. 2007;24(1):66-76. doi: 10.1002/da.20220. Depress Anxiety. 2007. PMID: 16845643 Review.
Cited by
-
Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder.J Psychiatry Neurosci. 2005 May;30(3):167-75. J Psychiatry Neurosci. 2005. PMID: 15944741 Free PMC article. Review.
-
Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram.Psychopharmacology (Berl). 2006 May;186(1):107-12. doi: 10.1007/s00213-006-0351-1. Epub 2006 Mar 16. Psychopharmacology (Berl). 2006. PMID: 16541242 Clinical Trial.
-
Acute shift in glutamate concentrations following experimentally induced panic with cholecystokinin tetrapeptide--a 3T-MRS study in healthy subjects.Neuropsychopharmacology. 2013 Aug;38(9):1648-54. doi: 10.1038/npp.2013.61. Epub 2013 Mar 5. Neuropsychopharmacology. 2013. PMID: 23463151 Free PMC article. Clinical Trial.
-
The effects of immunization against cholecystokinin fragment 30-33 in the behavior of white rats.Neurosci Behav Physiol. 2002 Mar-Apr;32(2):189-94. doi: 10.1023/a:1013983626780. Neurosci Behav Physiol. 2002. PMID: 11942698
-
Neuropsychopharmacological properties of neuroactive steroids in depression and anxiety disorders.Psychopharmacology (Berl). 2006 Jun;186(3):373-87. doi: 10.1007/s00213-005-0188-z. Epub 2005 Oct 25. Psychopharmacology (Berl). 2006. PMID: 16247651